Story perspectives

China's Pharma Sector Set for $100B Cross-Border Deals

12/19/2025

39 6

Summary

Story summary

China's pharmaceutical sector is evolving, with cross-border licensing and partnership deals projected to exceed $100 billion by the end of 2025.
Chinese drugmakers are increasingly pursuing complex co-development agreements with foreign firms amid a 'patent cliff'.
Innovative drugs account for 8.6% of China's pharmaceutical spending, compared with 81.8% in the United States.
Policy changes aim to improve access by strengthening the payment system and expanding commercial health insurance, increasing coverage.

1 of 1

Story summary

China's pharmaceutical sector is evolving, with cross-border licensing and partnership deals projected to exceed $100 billion by the end of 2025.
Chinese drugmakers are increasingly pursuing complex co-development agreements with foreign firms amid a 'patent cliff'.
Innovative drugs account for 8.6% of China's pharmaceutical spending, compared with 81.8% in the United States.
Policy changes aim to improve access by strengthening the payment system and expanding commercial health insurance, increasing coverage.